CLEAR CELL RENAL CELL CANCER (CCRCC)
Clinical trials for CLEAR CELL RENAL CELL CANCER (CCRCC) explained in plain language.
Never miss a new study
Get alerted when new CLEAR CELL RENAL CELL CANCER (CCRCC) trials appear
Sign up with your email to follow new studies for CLEAR CELL RENAL CELL CANCER (CCRCC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control Recruiting nowThis study is testing a new experimental drug called GI-101, given alone or with pembrolizumab or lenvatinib, in people with advanced or metastatic solid tumors (cancers that have spread). The goal is to see if the drug is safe and can shrink or control tumors. About 317 adults w…
Matched conditions: CLEAR CELL RENAL CELL CANCER (CCRCC)
Phase: PHASE1, PHASE2 • Sponsor: GI Innovation, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New radiation therapy targets kidney cancer cells
Disease control Recruiting nowThis phase 3 trial tests a drug called 177Lu-TLX250, which delivers radiation directly to kidney cancer cells. It is for adults with advanced clear cell kidney cancer that has returned or spread after prior treatments. The study first finds the best dose, then compares it to stan…
Matched conditions: CLEAR CELL RENAL CELL CANCER (CCRCC)
Phase: PHASE3 • Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New radioactive 'Smart Bomb' targets Hard-to-Treat cancers
Disease control Recruiting nowThis study is testing a new way to find and treat several types of advanced solid tumors, including kidney, pancreatic, and colorectal cancers. It uses a special radioactive compound that attaches to a protein found on these cancer cells. The study has multiple parts: first, to s…
Matched conditions: CLEAR CELL RENAL CELL CANCER (CCRCC)
Phase: PHASE1, PHASE2 • Sponsor: ITM Oncologics GmbH • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New PET scan agent aims to sharply detect multiple cancers
Diagnosis Recruiting nowThis study is testing a new imaging agent called 18F-T2, which is designed to highlight tumors that produce a protein called CAIX. About 200 adults with various cancers (like kidney, lung, or breast cancer) will receive an injection of 18F-T2 and then undergo a PET/CT scan. The g…
Matched conditions: CLEAR CELL RENAL CELL CANCER (CCRCC)
Phase: NA • Sponsor: Peking University First Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 12:33 UTC